Citadel Advisors’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Citadel Advisors’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-48,449	Closed	-$4K	–	15759
2022 Q3	$4K	Sell	48,449 -14,118	-23%	-$1.51K	﹤0.01%	12398
2022 Q2	$5K	Sell	62,567 -304,560	-83%	-$52.5K	﹤0.01%	12685
2022 Q1	$73K	Sell	367,127 -10,420	-3%	-$3.13K	﹤0.01%	12552
2021 Q4	$204K	Sell	377,547 -7,137	-2%	-$4.04K	﹤0.01%	11813
2021 Q3	$230K	Buy	384,684 +109,684	+40%	+$73.7K	﹤0.01%	11676
2021 Q2	$209K	Buy	+275,000	New	+$167K	﹤0.01%	12059

Other funds holding IBER.WS

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's IBER.WS Position: Q4 2022 in Review

Citadel Advisors sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q4 2022, closing a stake of 48,449 shares — an estimated $4K sold.

Citadel Advisors first reported a position in IBER.WS in Q2 2021 and held it in 6 quarters. The position peaked at $230K in Q3 2021. 33 funds tracked by Wall St. Rank hold IBER.WS as of Q4 2022.

Citadel Advisors reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q4 2022 after selling out during the quarter.
Citadel Advisors sold 48,449 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q4 2022, an estimated $4K.
Citadel Advisors first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2021 and held it in 6 quarters.
Citadel Advisors's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $230K in Q3 2021.
33 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.